Biologics Supplier for Orthopedic Practices in Fayetteville, AR

Vendor qualification: what to request before ordering

Orthopedic surgery centers typically run new suppliers through a documentation review before the first purchase order. For Wharton's jelly allografts, that review generally covers donor eligibility screening, the lot-specific certificate of analysis, and the sterility testing result from the third-party laboratory that cleared the lot for release.

Processing is described by the supplier as following FDA regulations along with AATB and AABB guidelines, and each lot carries a unique identifier that stays with the product from recovery through shipment. Practices that already maintain a biologics vendor file can request these records in the same format they use for other allograft suppliers.

• Certificate of analysis, by lot
• Donor eligibility screening summary
• Third-party sterility testing result
• Lot release record

NPI verification and account setup

Every Precision Biologics account is tied to an NPI number before pricing or ordering access is granted. This keeps purchasing limited to licensed physicians, clinics, and the surgery centers they operate, and it gives each order a clear chain of custody back to a verified practice.

Setup is a short process: submit practice and NPI details, confirm the ordering physician, and select which products your center intends to stock. Pricing is not published and is shared directly with verified accounts.

Cold-chain receiving for cryopreserved and lyophilized formats

Cryopreserved Wharton's jelly products ship overnight on dry ice in validated containers and are stored at -80 degrees C on arrival. Staff at the receiving practice should have a freezer ready and a process for logging the lot number into the patient record at the point of use, since traceability is tracked by lot.

Lyophilized formats are shelf-stable and do not require cryogenic storage, which gives surgery centers more flexibility for stocking between cases. Either way, confirm your intake process can capture lot numbers before your first shipment arrives.

Confirming regulatory posture with your medical board and counsel

Whether a specific intended use for a Wharton's jelly allograft qualifies under the minimal manipulation and homologous use criteria in 21 CFR 1271.10 is a determination for your practice and its counsel, not something Precision Biologics advises on. The same is true for exosome products: FDA has stated there are no FDA-approved exosome products, and they are generally regulated as biologic drugs, so purchase and use decisions rest with the treating physician and their own regulatory review.

We recommend Arkansas practices verify their own licensure and scope-of-practice standing with the state medical board before adding any new biologic product category. Our team can schedule a peer-to-peer call to walk through product documentation with your medical director, and we'll provide the certificate of analysis, donor eligibility summary, and lot release record for any account in good standing.

FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.

These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.